Navigation Links
GlaxoSmithKline Opens $600million Vaccine Plant In Singapore

New state-of-the-art vaccine plant to hire 200 staff in Singapore, GSK and the Singapore Economic Development Board (EDB) set up endowment fund.

Singapore (PRWEB) June 16, 2009 -- Singapore's pharmaceutical industry has moved into higher gear, with the opening of a state-of-the-art vaccine plant. The new plant is GlaxoSmithKline's (GSK) first primary vaccine manufacturing facility and its biggest investment in Asia. The plant, which involves a total investment of S$600 million, underscores GSK's strong commitment to Singapore.

GSK will initially employ about 200 staff and the company is investing in training and development to equip them with the skills and knowledge to operate the new facility.

In addition, as part of an ongoing effort to develop talent and leadership in Singapore, GSK is setting up a $30 million endowment fund here to nurture minds in the fields of green manufacturing and public health policy. The Singapore Economic Development Board (EBD) will boost the fund by a further $20 million.

GSK has had a strong presence in Singapore for the last 50 years since 1959. Besides the local pharmaceutical and consumer healthcare operations, Singapore serves as the headquarters for GSK's Asia-Pacific operations and houses the Singapore Research Centre at Biopolis. In addition to this new vaccine plant, GSK has two global manufacturing and supply sites located in Singapore. With more than 1000 staff, GSK's total investment in the city-state now exceeds S$1.5 billion.

Asia is emerging as a global powerhouse in the biomedical sciences industry, with its fast-expanding market and massive talent base. As a leading bio-cluster in Asia, Singapore provides access to world-class scientific and clinical excellence, excellent connectivity to key regional markets as well as strategic partnership opportunities with research institutes, corporate labs and public hospitals.

Leveraging Singapore's strong scientific and economic fundamentals, global biomedical sciences companies invested more than $500 million here in the year 2008 alone. A growing base of more than 50 global pharmaceutical, biotechnology and medical technology companies are carrying out R&D in Singapore, alongside 30 public-sector research and medical institutes. Amongst them, more than 10 leading multi-national companies have established their regional headquarters in Singapore. They include AstraZeneca, Bayer, Boehringer-Ingelheim, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Merck, Quintiles and Sanofi-Aventis. Their continued confidence is testament to Singapore's position as a leading global manufacturing site for innovative medicines.

To find out more about working and living in Singapore, log on to Contact Singapore's website at or search for jobs at

For more information about Singapore's biomedical sciences sector, log on to the Singapore Economic Development Board's website at and the Agency for Science, Technology and Research's website at

About Contact Singapore

Contact Singapore is an alliance of the Singapore Economic Development Board and Ministry of Manpower. It aims to attract global talent to work, invest and live in Singapore.

With offices in Asia Pacific, Europe and North America, Contact Singapore is the one-stop center for those who wish to pursue a rewarding career in Singapore, as well as business leaders and entrepreneurs who are keen to invest in or initiate new business activities here. Contact Singapore actively links Singapore-based employers with global talent and provides updates on career opportunities and industry developments in Singapore. We work with private sector partners to facilitate the interests of potential individual investors in Singapore.

For more information on working, investing and living in Singapore, please visit


Read the full story at

Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. GlaxoSmithKline Consumer Healthcare Makes Agency Changes to Support Growth on Global Brands
2. GlaxoSmithKline Travel Health: 55 percent of travellers needlessly put themselves at risk from a potentially fatal virus
3. Research Findings on Nine GlaxoSmithKline Cancer Compounds to be Presented at ASCO 2009
4. GlaxoSmithKline to Divest US Rights for Wellbutrin XL(R) to Biovail for $510 Million
5. GlaxoSmithKline Update: Influenza A (H1N1)
6. GlaxoSmithKline and Pfizer Announce Innovative Agreement to Create a New World-Leading, Specialist HIV Company
7. GlaxoSmithKline and Shire Enter Agreement to Co-Promote Vyvanse(R) (lisdexamfetamine dimesylate) CII for Adult Attention Deficit Hyperactivity Disorder
8. IADR and GlaxoSmithKline Consumer Healthcare announce winners of 2009 Innovation in Oral Care Awards
9. GlaxoSmithKline Consumer Healthcare to Reach 85 Percent of the Worlds Smokers with Quit Aids
10. GlaxoSmithKline Consumer Healthcare Helps to Bridge Oral Care Gap in Appalachia
11. Activplant Corporation Announces Global Agreement with GlaxoSmithKline
Post Your Comments:
Related Image:
GlaxoSmithKline Opens $600million Vaccine Plant In Singapore
(Date:11/25/2015)... ... ... Many people know of the common symptoms of low thyroid hormone (also ... many people who find their cholesterol levels and weight are creeping up are more ... they don’t have any of the other symptoms. , Thyroid hormone plays a major ...
(Date:11/24/2015)... ... November 25, 2015 , ... Genesis Chiropractic Software ... software creates an agreement between the practice owner and the patient that automatically ... notification, and projections. Click here to learn more. , ...
(Date:11/24/2015)... ... ... Charitable giving is at its peak during the holidays. In fact, ... the year totalling over $358 billion in 2014. With more than 1.5 million ... individuals who want to “give back” during the holidays. , “With so many charities ...
(Date:11/24/2015)... ... November 24, 2015 , ... The ... comes to several aspects of orthopedic care. They have received recognition for excellence ... general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion based ...
(Date:11/24/2015)... ... 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus Medical ... the United States grew 400 percent between 1999 and 2010, far more than the ... percent of all fatal drug overdoses. (1) , While oxycodone and the extended release ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... N.Y. , Nov. 24, 2015 Avery ... System, is pleased to announce the appointment of ... Dr. ... pediatric cardiology at Children,s Hospital, Uppsala University, Uppsala and ... From 1984-1986, he was a fellow at the Cardiovascular ...
(Date:11/24/2015)... , November 24, 2015 ... --> adds Latest Guidebook for ... of 217 pages published in November 2015 to ... online business intelligence library at . ... of the fastest growing global economies with a ...
(Date:11/24/2015)... , Nov. 24, 2015  Ascendant Solutions, Inc. (Pink Sheets: ... its Board of Directors has declared a special 1 percent ... dividend is payable December 14, 2015, to shareholders of record ... form of additional shares of common stock. ... Board is a strong endorsement of our confidence in Ascendant,s ...
Breaking Medicine Technology: